Global Oncology Based In-Vivo CRO Market 2022-2028

May 2022 | 77 pages | ID: G1FD25A70AA0EN
Gen Consulting Company

Abstracts

In-vivo CRO refers to the preclinical testing performed for preclinical testing of disease pathology and drug discovery. It provides information regarding the collection and investigation of data for the development of new drugs for the treatment of various indications. The global oncology based in-vivo cro market was valued at USD 1,077 million in 2021 to USD 1,707 million by 2028, progressing at a CAGR of 6.8% from 2022 to 2028, according to Gen Consulting Company.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global oncology based in-vivo cro market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the oncology based in-vivo cro industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the indication, and region. The global market for oncology based in-vivo cro can be segmented by indication: blood cancer, solid tumors (syngeneic model, patient-derived xenograft (PDX), xenograft), others. Oncology based in-vivo cro market is further segmented by region: Asia Pacific, Europe, North America, Rest of the World (RoW).

By indication:

• blood cancer
• solid tumors (syngeneic model, patient-derived xenograft (PDX), xenograft)
• others

By region:

• Asia Pacific
• Europe
• North America
• Rest of the World (RoW)

The report explores the recent developments and profiles of key vendors in the Global Oncology Based In-Vivo CRO Market, including Charles River Laboratories International, Inc., Crown Bioscience, Inc., Eurofins Scientific SE, Evotec SE, ICON Plc, Laboratory Corporation of America Holdings (Labcorp), Taconic Biosciences, Inc., The Jackson Laboratory, WuXi AppTec Co., Ltd., XenTech SAS, among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global oncology based in-vivo cro market.
• To classify and forecast the global oncology based in-vivo cro market based on indication, region.
• To identify drivers and challenges for the global oncology based in-vivo cro market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global oncology based in-vivo cro market.
• To identify and analyze the profile of leading players operating in the global oncology based in-vivo cro market.

Why Choose This Report

• Gain a reliable outlook of the global oncology based in-vivo cro market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY INDICATION

Blood cancer
Solid tumors (syngeneic model, patient-derived xenograft (PDX), xenograft)
Others

PART 6. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America
Rest of the World (RoW)

PART 7. KEY COMPANIES

Charles River Laboratories International, Inc.
Crown Bioscience, Inc.
Eurofins Scientific SE
Evotec SE
ICON Plc
Laboratory Corporation of America Holdings (Labcorp)
Taconic Biosciences, Inc.
The Jackson Laboratory
WuXi AppTec Co., Ltd.
XenTech SAS
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER